ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) Director Barry Simon sold 165,000 shares of ImmunityBio stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the sale, the director directly owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. This represents a 5.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
ImmunityBio Stock Up 17.5%
NASDAQ:IBRX traded up $1.72 during midday trading on Tuesday, hitting $11.55. The stock had a trading volume of 82,882,982 shares, compared to its average volume of 31,529,002. The stock has a 50-day moving average of $4.82 and a 200 day moving average of $3.24. The company has a market capitalization of $11.38 billion, a price-to-earnings ratio of -30.39 and a beta of 0.16. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $12.28.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. On average, sell-side analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ImmunityBio
More ImmunityBio News
Here are the key news stories impacting ImmunityBio this week:
- Positive Sentiment: Company reports ANKTIVA regulatory/approval expansion and broader global commercial reach, supporting larger addressable market and sales potential. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
- Positive Sentiment: Management says ANKTIVA drove massive revenue growth—company reported ~700% year‑over‑year revenue increase and new global commercial partnerships covering multiple countries, signaling meaningful commercial traction. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth…
- Positive Sentiment: Q4 results beat revenue and EPS loss expectations (reported loss $0.06 vs. consensus -$0.08; revenue ~$38.3M), which investors view as confirmation that commercial sales are scaling. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
- Positive Sentiment: Market coverage and outlets highlight ANKTIVA-driven revenue surge and share gains toward a 52‑week high, reinforcing momentum and investor enthusiasm. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
- Positive Sentiment: An analyst shop (D. Boral Capital) reaffirmed a “buy” and set a $23 price target, providing an actionable upside thesis for price momentum. Benzinga
- Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at high‑profile cancer summits — visibility and credibility boost but not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
- Neutral Sentiment: Chairman commentary and press pieces tease multi‑year ANKTIVA expansion and potential future indications; positive for sentiment but speculative for near‑term fundamentals. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans…
- Negative Sentiment: Despite the revenue jump, the company remains unprofitable (negative EPS and a current-year analyst consensus loss), which keeps valuation and execution risk elevated for long‑term investors. ImmunityBio Q4 Press Release
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on IBRX. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research note on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Piper Sandler increased their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Jefferies Financial Group lifted their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, BTIG Research boosted their price objective on shares of ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, ImmunityBio currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.60.
Get Our Latest Analysis on IBRX
About ImmunityBio
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Read More
- Five stocks we like better than ImmunityBio
- Unlocked: Elon Musk’s Next Big IPO
- This makes me furious
- The biggest Gold & Silver event of the year is March 4
- Silver paying 20% dividend. Plus 68% share gains
- America’s 1776 happening again
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
